We are developing strategies for interrogating the “organ on a chip” platform with innovative drugs that affect cellular and systemic energy metabolism as well as differentiation (pre-clinical, early stage clinical, and registered drugs). In the second phase of the project, we aim to use organoids derived from human disease cohorts or carrying specific engineered mutations for drug testing.
Chemical biology
We work towards standardized high throughput drug testing on the organ on a chip platform
Label-free 3D imaging of live cancer cells by holotomography (credit: Petter Angell Olsen).
Published Sep. 18, 2017 1:38 PM
- Last modified Jan. 25, 2024 1:25 PM